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Abstract
Background: A maximum entropy approach is proposed to predict the cytotoxic effects of a panel of colchicine 
derivatives in several human cancer cell lines. Data was obtained from cytotoxicity assays performed with 21 drug 
molecules from the same family of colchicine compounds and correlate these results with independent tubulin 
isoform expression measurements for several cancer cell lines. The maximum entropy method is then used in 
conjunction with computed relative binding energy values for each of the drug molecules against tubulin isotypes to 
which these compounds bind with different affinities.
Results: We have found by using our analysis that αβI and αβIII tubulin isoforms are the most important isoforms in 
establishing predictive response of cancer cell sensitivity to colchicine derivatives. However, since αβI tubulin is widely 
distributed in the human body, targeting it would lead to severe adverse side effects. Consequently, we have identified 
tubulin isotype αβIII as the most important molecular target for inhibition of microtubule polymerization and hence 
cancer cell cytotoxicity. Tubulin isotypes αβI and αβII are concluded to be secondary targets.
Conclusions: The benefit of being able to correlate expression levels of specific tubulin isotypes and the resultant cell 
death effect is that it will enable us to better understand the origin of drug resistance and hence design optimal 
structures for the elimination of cancer cells. The conclusion of the study described herein identifies tubulin isotype 
αβIII as a target for optimized chemotherapy drug design.
Background
Tubulin as a Target for Chemotherapy
Tubulin is a structural protein whose α/β hetero-dimer
forms the constituent subunit of microtubules MTs [1].
MTs are critically involved in cellular processes such as
mitosis, intracellular transport and cell motility. For can-
cer chemotherapy, tubulin is the target of some of the
most successful anti-tumor drugs, such as the taxanes
and the vinca alkaloids [2,3]. When the three-dimen-
sional structure of a drug target is known [4,5], it is theo-
retically possible to use computational methods to design
drugs that will bind specifically to that target and thereby
become therapeutically useful. Since tubulin is such a
successful anti-tumor drug target, and since its three-
dimensional structure has been determined (including
the case when it is bound to colchicines), it is logical to
apply rational drug design and synthesize drugs that will
target tubulin even better than presently used drugs. An
important issue that has been, by and large, left unan-
swered is which of the several tubulin isotypes should be
specifically targeted in cancer chemotherapy. The ulti-
mate goal, therefore, is to design drugs that bind well to
the over-expressed tubulin isotype and are lethal to can-
cer cells but not to normal cells. We have evaluated our
initial approach to rational drug design based on tubulin
as a target and specifically its colchicine binding site. We
have chosen the colchicine site because: 1) colchicine is a
drug with a long clinical history [6]; 2) the precise mecha-
nisms of colchicine binding, including conformational
effects, have been worked out better than for any other
tubulin-binding drug [7-14]; 3) the synthetic chemistry of
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colchicine and its derivatives is simpler than that of other
tubulin-binding drugs [15,16]; 4) colchicine has strong
anti-mitotic activity which can be used as a standard for
c o m p a r i s o n  o f  t h e  d e r i v a t i v e s  t h a t  w e  d e s i g n  [ 1 7 ] ;  5 )
c o l c h i c i n e  h a s  b e e n  u s e d  i n  c l i n i c a l  t r i a l s  b u t ,  d u e  t o
dose-limiting general toxicities has not been successful so
far [6]; 6) tubulin isotypes differ significantly from each
other in their binding to colchicine and some of its deriv-
atives. Our hope is that by altering the structure of the
drug to make it more specific for cancer cells, its thera-
peutic concentration can be lowered below the toxicity
limit. The issue of particular importance in our study was
to determine the sensitivity of cancer cells to those drugs
that target one or more tubulin isoforms. As a result of
this work, we have determined specific molecular targets
that should both improve the efficacy and lower the gen-
eral toxicity of these anti-mitotic compounds.
In the initial stage of the project we have performed
c o m p u t e r  m od e l l i n g  t o  d es i gn  t w o  s e r i e s  o f  c o l c h i ci n e
derivatives. The first series had minor changes that were
predicted to decrease the binding to tubulin while the
other had side groups added in order to increase their
binding affinity, in particular with respect to the isotype
αβIII tubulin isoform that is commonly over-expressed in
cancer cells [18-27] and hence was predicted to be a suit-
able anti-cancer target. To assist the reader in following
our strategy, we will briefly discuss the issues of: (a) the
colchicine binding site in tubulin and the design of
colchicine derivatives, (b) cytotoxicity assays and (c)
tubulin isotype expression measurements in the section
of Materials and Methods. The details are discussed else-
where [28].
Goal
The ultimate goal of our work is to investigate the relative
importance of tubulin isotypes in eliciting response of
cancer cells to cytotoxic stress. Specifically, we have cho-
sen to analyze this issue using a novel family of tubulin-
binding compounds created as derivatives of colchicine.
In order to understand the complex behaviour of various
cancer cells exposed to these drugs, we propose to apply
the maximum entropy (ME) approach [29-35] to predict
the expression levels of specific isotypes of tubulin in
response to cytotoxic agents introduced. Six cancer cell
lines, A549, MCF7, CEM, HeLa, M006X, and M010B, are
considered in this study and they were subjected to
colchicine and 20 of its novel derivatives with signifi-
cantly different binding affinities for each tubulin isotype,
particularly αβI,αβII,αβIIIand αβIV. Tubulin is assumed
to be the primary target of colchicine's action and there-
fore binding affinity is also assumed to correlate with the
toxic effect on cells exposed to the drug, the final out-
come being apoptosis. The benefit of being able to corre-
late expression levels of specific tubulin isotypes and the
resultant cell death is that this could enable us to better
understand the origin of drug resistance and hence assist
us in the design of optimized structures for the elimina-
tion of cancer cells. Anti-tumor drugs that target tubulin
differ in their affinities for specific tubulin isotypes. Both
αβII and αβIII are frequently over-expressed in cancer
cells. Paclitaxel and vinblastine, both of which are very
successful, favour the αβII over the αβIII isotype. How-
ever, αβII is very abundant in the nervous system and a
few other tissues, hence side effects, such as neuropathy,
commonly occur with these drugs. Tubulin isotype αβIII,
which is much less widespread than αβII, is therefore an
attractive target for novel drugs. As will be demonstrated
in the remainder of this paper, αβIII tubulin is indeed
confirmed as the best molecular target within the tubulin
family.
Materials and methods
The colchicine binding site and the design of colchicine 
derivatives
Unlike paclitaxel, the binding of colchicine does not
result in MT stabilization; instead it results in their desta-
bilization. Initial structures of a two-heterodimer proto-
filament complexed with the Stathmin-like domain of
Rb3 were determined based on the information in the
Protein Data Bank (PDB identifier: 1 FFX). Recently, this
work was followed by an additional structure that identi-
fied colchicine as binding between the α and β tubulin
molecules of the hetero-dimer itself (PDB identifier
1SA0). Ravelli et al. [8] identified several principal inter-
actions between the bound colchicine and β tubulin. First
were interactions with sheets S8 and S9, helix H7 and H8
and loop T7 (see Nogales, et al. [4]). During our analysis,
we identified a total of 29 residues of β tubulin within the
6 Å cutoff from the bound colchicine. Most of them are
contained in the middle of the protein. The colchicine
binding site is composed of residues 235-240, 246-257,
312-316 and 347-352. Of these 29 residues, seven posi-
tions show differences among the β tubulin isotypes. All
of the observed substitutions occur within the H7 and H8
helices, and the S8 and S9 sheets. These positions were
initially identified by Ravelli et al. [8] as those that are dis-
placed upon colchicine binding to the β tubulin. Differ-
ences here occur over a wider range of β  isotypes,
encompassing βIII, βV, βVI, βVII and βVIII (see Table 1).
Many of these substitutions are conservative, with the
exception of βVII position Val255-Met and βIII, βV and
βVI position Ala316-Thr/Cys. Interestingly, there are four
positions within the tubulin sequence alignment that
have no clear consensus residue over all the β isotypes,
one of which is position 316, which falls within the
colchicine binding site and can accommodate either Val
or Ile.Tseng et al. Molecular Cancer 2010, 9:131
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When comparing the results of our modeling of the
colchicine binding site to the data obtained in the 1SA0
structure, we see no obvious differences, with the excep-
tion of Cys239-Ser in βIII, βV and βVI, which was identi-
fied by Chaudhuri, et al. [14] as being involved with
colchicine binding through cysteine labeling studies. This
position, while spatially conserved, produces an altered
chemical environment, the difference being the presence
o f  a  h y d r o x y l  o r  s u l fh y d ry l  m o i e t y .  A  c h a n g e  l i k e  t h i s
could be exploited by producing covalently bound forms
of a drug, under certain conditions in the form of either a
disulfide or ester linkage. Additionally, the substitution
Val255-Met within the βVII isotype might alter the posi-
tional dynamics of helix H8 and therefore influence
colchicine binding in this way. Residues that are present
within the interface between H7/H8 and S8/S9, prior to
their displacement upon colchicine binding, may also
produce interactions that impart varied stability to this
region.
Structures of the compounds
The two main classes of structural analogs of colchicine
and the side groups used in this study are given in Figures
1 and 2. The substituents D1-20 were chosen based on
how colchicine interacts and sits in the β-tubulin binding
pocket. The generation and characterization of colchicine
derivatives has been described previously (see [36]) based
on the differences observed among the most commonly
expressed human tubulin isotypes: αβI, αβII, αβIII and
αβIV. The colchicine derivatives were modified at either
the × (C1) or Y (C3) methoxy position of the A-ring. Acy-
lation of the common intermediates 1- or 3-demethyl-
colchicine afforded ester derivatives while alkylation gave
ether derivatives. The general synthetic schemes for the
ester and ether derivatives of colchicines were based on
previously published schemes [15]. The modification to
the first analog is done by replacing the -OCH3 in the C13
position of the A-ring of colchicine by different -OX
groups. In the second analog, the -OCH3 inof colchicine
are replaced by the C11 position of A-ring and the -OCH3
in the C-ring of colchicine are replaced by different -OY
groups and -SCH3, respectively. All of these resulting
derivative structures including colchicines that are
defined as D01-D20 as appeared in figures 1 and 2 and
D00 respectively are constructed using MOLDEN pro-
gram [37], then optimized in the gas phase with the
GAMESS-US program [38] using the Austin Model 1
(AM1) semi-empirical method [39,40] before being used
in the in silico studies in the next section.
In silico binding affinity prediction
The relative binding affinities for each of colchicine
derivatives have been calculated for all major human β
tubulin isotypes in order to determine which of them
bind better to specific tubulin isotypes. The binding free
Figure 1 The structures of the first class of colchicines. The struc-
tures of the first class of colchicine analogs and the corresponding X-
side groups.
Table 1: Tubulin Isotype Interactions with Colchicine
Isotype Substitutions at Binding Site
βIII X Cys239-Ser X X Ala315-Thr Thr351-Val
βV X Cys239-Ser X X Ala315-Thr Thr351-Val
βVI Val236-Ile Cys239-Ser X X Ala315-Thr Thr351-Val
βVII X X Val255-Met Val313-Ala X X
βV I I I XXX V a l 3 1 3 - A l a XXTseng et al. Molecular Cancer 2010, 9:131
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energies and stabilities of colchicine analogs and deriva-
tives, placed within the binding site of αβ-tubulin het-
erodimer solvated in a 115 A × 75 A × 75 A rectangular
box of water molecules, have been evaluated using hybrid
quantum mechanical/molecular mechanical (QM/MM)
technique. The computer program DYNAMO [41] and
GAMESS-US [38] has been used in this study. For the α-
tubulin subunit, we used the corresponding α-tubulin
chain 1SA0 [8] taken from the RCSB Protein Databank.
Each bio-molecular system has been partitioned into two
regions: (a) a small portion containing the binding site,
i.e., colchicine derivative and the immediate surrounding
amino acid residues; and (b) the remaining larger portion,
representing the rest of the α/β-tubulin hetero-dimer.
The former has been treated quantum mechanically and
the latter via molecular mechanics. The reason for such a
partitioning scheme is that we want to model the
dynamic distribution of electrons in the binding site
(through QM), and at the same time provide a more real-
istic model environment enclosing the binding site
(through MM). In this hybrid QM/MM approach, the
QM portion interacts with the MM portion and vice-
versa.
The thermodynamic cycle perturbation approach was
proposed to overcome the difficulties related to the com-
putational complexity of the problem [42]. Figure 3 shows
the scheme that is used as the basis for the determination
of the relative free energies of binding [36]. In this
scheme, ABT represents the α-tubulin dimer, and the val-
ues of ΔG s represent free energy changes for the indi-
cated processes. The relative binding of C and C' to ABT
is determined by ΔΔGbind = ΔG2-ΔG1 rather than calcu-
lating ΔGC'-ΔGC directly. Table 2 summarizes the results
of the binding free energy estimates for the 20 derivatives
of colchicine and colchicine itself against seven β tubulin
derivatives. The energy values are given in kcal/mol.
Computational screening gave us confidence that some
of the designed derivatives are both tubulin isotype spe-
cific and that they may possess high affinity for the target
making them therapeutically viable. Subsequent experi-
mental validation using cytotoxicity assays demonstrated
that some of these first generation derivatives are indeed
superior to colchicine in their effects on tumor cells.
Cytotoxicity assays
The new colchicine derivatives were tested, together with
their parent compound, colchicine, on a variety of cancer
cell lines in a variety of assays: cytotoxicity, induction of
apoptosis, and effect on cell morphology.
For initial screening, we chose a variety of common
cancer cell lines based on the diversity of their cancers of
origin as well as their differing morphologies. Testing
cytotoxicity of the colchicine derivatives against cells
with a variety of morphologies and origins can help us
determine any differences in derivative efficacy based on
cell type. The cell lines we initially chose to experiment
with included CEM, MCF-7, HeLa, A549, as well as
M006X and M010B cells, sister glioma cell lines. Table 3
lists the cell lines used, including their origins and growth
conditions.
Derivative drug stock solutions were prepared by gravi-
metrically weighing out a specific amount of the com-
pound, dissolving in DMSO, and diluting to a final
volume with distilled water (final [DMSO] = 4.5%). A
series of drug dilutions were then prepared to determine
compound characteristics. The lab spectrophotometer
was used to complete a wavelength scan of the diluted
Figure 3 Thermodynamic cycle approach. The schematic plot of 
thermodynamic circle approach used for calculating relative binding 
free energy.
Figure 2 The structures of the second class of colchicines. The 
structures of the second class of colchicine analogs and the corre-
sponding Y-side groups.Tseng et al. Molecular Cancer 2010, 9:131
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drug solution, which determined the wavelength of maxi-
mum absorbance of the drug. Five known drug concen-
trations were then scanned at this wavelength. These
concentrations were plotted (X) versus their absorbance
values at the pre-determined wavelength (Y) to get a lin-
ear graph; the slope of the line is a rough estimate of the
compound's exhaustion coefficient. This coefficient can
be used in conjunction with a current absorbance reading
of the drug stock solution to determine the concentration
of this solution whenever it is needed. Once the com-
pound characteristics were determined, the drug was
used in MTS cytotoxicity assays on our cell lines.
Cytotoxicity testing was completed using a common
cell viability assay, the MTS assay. A primary MTS assay
is used to test the number of cells ideal for use in the
cytotoxicity assay. Cells are trypsinized, counted and set
up in 7 lanes of a 96-well plate at various cell numbers
(with 8 wells/replicates per lane). An eighth lane includes
a media alone control. The goal of this MTS cell number
test is to find the number of cells (per well in 96-well
plates) that will be in exponential growth after 72 and 96
hours for adherent cell lines, and after 48 and 72 hours for
suspension cell lines. Using this cell number for cytotox-
icity assays allows us to find the effects of the anticancer
Table 2: Relative binding free energy estimates
I IIa IIb III IVa IVb
D01 -13.2 ± 1.8 5.9 ± 1.5 -2.8 ± 1.6 1.1 ± 1.7 5.5 ± 2.6 -16.9 ± 2.7
D02 -9.6 ± 3.3 -24.8 ± 1.6 -7.9 ± 2.2 1.4 ± 2.2 15.1 ± 4.0 -5.4 ± 3.9
D03 -19.9 ± 6.2 -10.7 ± 3.9 -17.0 ± 3.9 6.6 ± 2.4 -9.5 ± 4.7 -20.7 ± 7.6
D04 -30.0 ± 4.8 -8.3 ± 2.1 -7.0 ± 3.9 2.2 ± 4.0 -8.2 ± 4.2 -10.0 ± 3.4
D05 -13.8 ± 3.4 -11.5 ± 2.0 3.5 ± 2.4 5.0 ± 1.7 -7.0 ± 3.5 -13.9 ± 2.1
D06 8.6 ± 4.0 4.8 ± 2.1 20.0 ± 1.7 -4.3 ± 1.3 8.1 ± 2.6 -12.7 ± 5.7
D07 -2.8 ± 0.8 -9.8 ± 1.7 2.6 ± 1.7 1.2 ± 1.6 1.8 ± 2.3 -10.2 ± 1.9
D08 -2.5 ± 2.7 -7.8 ± 1.6 1.1 ± 4.5 2.2 ± 3.0 3.5 ± 3.1 -16.5 ± 6.2
D09 2.9 ± 5.8 -7.0 ± 1.9 0.1 ± 3.3 0.3 ± 4.4 14.1 ± 3.7 4.7 ± 6.3
D10 -10.6 ± 4.6 -13.2 ± 3.0 -4.9 ± 4.3 -21.7 ± 1.8 -15.9 ± 4.1 -15.8 ± 6.1
D11 37.6 ± 1.6 -0.6 ± 0.8 10.7 ± 1.7 13.1 ± 0.3 3.2 ± 3.4 -19.1 ± 1.6
D12 -15.6 ± 1.6 -23.2 ± 2.1 -4.1 ± 1.9 -15.1 ± 1.6 -2.8 ± 2.7 -30.4 ± 3.3
D13 0.1 ± 2.3 -5.2 ± 3.4 9.7 ± 1.5 2.3 ± 2.2 -3.7 ± 2.3 -18.1 ± 3.6
D14 -0.1 ± 4.0 -11.0 ± 1.9 0.6 ± 1.5 26.3 ± 1.9 26.5 ± 2.7 -20.0 ± 6.1
D15 12.4 ± 3.3 -3.5 ± 1.6 -1.4 ± 0.8 6.3 ± 1.6 -4.3 ± 2.3 -4.4 ± 3.2
D16 -2.8 ± 4.2 -3.9 ± 0.9 5.5 ± 1.8 -9.1 ± 3.8 -9.9 ± 3.5 -15.5 ± 2.2
D17 7.8 ± 5.1 -1.3 ± 1.4 3.1 ± 4.3 1.9 ± 1.5 26.1 ± 3.6 -6.6 ± 3.8
D18 -2.1 ± 2.9 -1.1 ± 3.4 3.3 ± 2.8 16.8 ± 1.4 -5.6 ± 1.9 -10.1 ± 2.3
D19 -10.3 ± 3.8 3.4 ± 3.2 -11.0 ± 2.3 -0.2 ± 1.5 -15.1 ± 3.2 -6.1 ± 5.1
D20 -1.7 ± 5.1 0.9 ± 1.7 10.6 ± 3.5 7.8 ± 1.8 -6.4 ± 3.9 -8.4 ± 3.7
Relative binding free energy estimates of the 20 derivatives of colchicine and colchicine itself (listed in the first column) against seven tubulin 
isotypes listed in the top row. The energy values are given in kcal/mol and the detailed derivation is given in [36].
Table 3: Origins and growth conditions of common cancer cell lines used for MTS cytotoxicity assays
Cell Line Origin Media
A549 Human lung carcinoma RPMI with 10% fetal bovine serum (FBS)
MCF-7 Human mammary gland adenocarcinoma RPMI with 10% FBS
CEM Human T-lymphoblastoid from ALL RPMI with 10% FBS
HeLa Human cervical carcinoma DMEM with 10% FBS
M006X Human glioma cells DMEM-F12 with 10% FBS and 1% Glutamine
M010B Human glioma cells DMEM-F12 with 10% FBS and 1% GlutamineTseng et al. Molecular Cancer 2010, 9:131
http://www.molecular-cancer.com/content/9/1/131
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drug on exponentially growing cells, conditions similar to
those of actual tumors. The 24 hour difference in growth
time between adherent and suspension cells is given to
allow adherent cells time to attach to their growth sur-
face. Cells then have time to set up and grow in a manner
respective of their tumor type, allowing us to gather more
accurate information of the potential responses of their
tumor types to various drugs. Suspension cells, on the
other hand, do not require the extra 24 hour growth
period. They are plated directly in their natural tumor
form (in suspension), and drugs can therefore be added to
cells in this state with no set up time.
For cytotoxicity testing, adherent cells were plated into
9 lanes of a 96 well plate at the pre-determined cell num-
ber (a tenth lane includes a media alone control). Twenty-
four hours later, various concentrations of drug were
added to eight of the lanes containing cells (the ninth lane
containing cells is a control). At this time, drug solutions
were prepared with suspension cell lines at an appropri-
ate cell concentration (as determined in the MTS cell
number test), and the suspension cell line experiments
were plated. All cell lines were then grown with the drug
for 48 and 72 hours. Cell viability was determined using
the CellTiter 96 AQueous One Solution Cell Proliferation
Assay. Twenty micro-litres of MTS solution was added to
100 μl of media/drug solution in each well and incubated
for 60-120 minutes at 37°C. Viable cells bioreduce the
MTS tetrazolium compound into a colored formazan
product that is soluble in tissue culture medium. The
absorbance was recorded at 490 nm with a 96-well plate
reader. Background (no cells, media only) absorbance was
subtracted from all other absorbances.
Absorbances from the eight wells in each lane were
averaged, and the resulting absorbance value is propor-
tional to the number of viable cells in each well of that
lane/condition. Absorbance from each condition was
expressed in a graph in terms of percent cell survival
[compared to the absorbance of the control lane (cells-
alone, no drug)]. To estimate IC50 (effective concentration
at which 50% of the drug effects are seen) from the
response curve, we apply a dose-response model that is
ideal for data that has an initial response plateau, a transi-
tion region, and a final response plateau, given by
for regression, where HILL is a measure of the steep-
ness of the transition region and was fixed at a value of
2.5. Itop is the response obtained at very low/no drug con-
centration and X denotes dose in logarithm unit. After
regression, parameters, Itop, Ibot and log IC50 were normal-
ized to Itop . Ibot is a measure of the maximum effect of the
drug. A Monte Carlo simulation [43] was applied to
determine the confidence level of the three fitted parame-
ters. The idea is to simulate a bunch of data sets that are
randomly sampled based on a Gaussian distribution from
the ideal data set generated from the best-fit parameters.
Afterward, the same regression is repeated to obtain best-
fit parameters for each data set. Finally, the mean and
standard deviation of best-fit parameters are determined.
The log IC50 of cell lines exposed to twenty colchicine
derivatives are listed in Table 4. Note that the use of Table
4 is only for the demonstration of the proposed approach.
Tubulin Isotype expression data
Following cytotoxicity assays which gave us an indication
that the designed colchicine derivatives have led to
encouraging outcomes for a panel of diverse cancer cell
lines, our next task was to determine the expression levels
of tubulin isotypes before and after exposure of the cells
to the toxic agents including colchicines and D20 at the
estimated 25% of lethal concentration of dose. This type
of experiment would provide information regarding the
regulation by the cells of the target protein, tubulin, and
its specific isoforms.
Briefly, frozen cell pellets from six human cell lines
A549, MCF7, CEM, HeLa, M006X, M010B were thawed
on ice and homogenized on ice in 10 mM Tris pH 7.4 and
0.3% SDS with 1% protease and phosphatase inhibitors
(Sigma Chemical Co., St. Louis, MO) and centrifuged at
12,000 × g at 4°C. The supernatants were treated with 50
μg/ml DNase and 100 μg/ml RNase. Protein was quanti-
fied using Micro BCA protein assay kit (Pierce Biotech-
nology, Rockford, IL). An equal amount of protein (20 μg)
was boiled in SDS loading buffer containing 0.1 M DTT
and resolved by electrophoresis in 7.5% SDS polyacryl-
amide gels (Bio-Rad Laboratories, Hercules, CA). Bioti-
nylated protein ladder (Cell Signaling Technology,
Beverly, MA) and Kaleidoscope pre-stained protein stan-
dard (Bio-Rad Laboratories, Hercules, CA) were included
for assessment of molecular mass of target proteins. The
gels were transblotted to Hybond-C nitrocellulose mem-
branes (Amersham Biosciences, Piscataway, NJ) and the
membranes were blocked in 5% ECL Advance blocking
solution (Amersham Biosciences, Piscataway, NJ) for 1 h
at room temperature. Immunodetection was performed
by incubating the membrane overnight at 4°C with
murine monoclonal antibodies to β  tubulin isotypes I
through IV with murine monoclonal antibodies to β
tubulin isotypes I through IV or with a murine monoclo-
nal antibody to β-actin as a housekeeping gene product
control (Oncogene Research Products, Boston, MA) fol-
lowed by incubation with the secondary antibody, anti-
mouse IgG HRP conjugate (Cell Signaling Technology,
B e v e r l y ,  M A ) .  A n t i b o d y  d i l u t i o n s  w e r e  a s  f o l l o w s :  βI
Response bot top
top =+
−
+ −× − ()
I
II
HILL IC X 11 0 50 log
(1)Tseng et al. Molecular Cancer 2010, 9:131
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(1:5000, 2nd antibody 1:5000), βII (1:5000, 2nd antibody
1:1000),  βIII (1:5000, 2nd antibody 1:1000), and βIV
(1:5000, 2nd antibody 1:500). The secondary antibody
solution also included 1:10,000 anti-biotin HRP-linked
antibody to visualize the protein ladder. All antibodies
were diluted with 2.5% ECL Advance blocking solution.
Target proteins were visualized by enhanced chemilumi-
nescence with ECL Advance Western Blot detection kit
and captured on Hyperfilm-ECL film (both from Amer-
sham Biosciences). Image analysis was performed with a
personal densitometer (Amersham Biosciences). Relative
quantities of target proteins were determined using
ImageQuant and normalized to β-actin levels in each
sample. Furthermore, we normalized it across four iso-
types. The data are shown in Table 5.
The maximum entropy method for tubulin Isotype 
expression level estimates
Maximum entropy method: a tool for assigning and updating 
probability distributions
Our goal was to utilize information such as binding free
energy values between a toxic agent and a molecular tar-
get in order to estimate tubulin isotype expression levels
present in cytotoxcity assays. This is exactly the type of
question that the method of maximum entropy is
designed to answer [28-34]. Specifically, based on the
assumption that cytotoxicity is correlated with drug affin-
ity for the molecular target, we ask: "Given the informa-
tion regarding the binding free energy between individual
tubulin isotypes and colchicine derivatives and the IC 50
values from cytotoxic measurements on the cell lines
exposed to these drugs, what are most likely expression
levels of specific tubulin isotypes?".
Following Jaynes' method of maximum entropy (Max-
Ent) [29], which is only designed to codify limited infor-
mation relevant to systems of interest into a probability
distribution with the least bias, the ME method [30-35] is
designed to update the corresponding probability distri-
bution from an a priori chosen function each time addi-
tional information is acquired. Note that the probability
distribution represents our state of knowledge of the sys-
tems in a specific state. Suppose the system of interest is
characterized by label i and the variable Hi represents
some properties of the system in state i. For example, the
label i may represent a binding mode of target proteins
Table 4: The log IC50 values of colchicine and various colchicine derivatives
A549 HeLa MCF-7 CEM M010B M006X
D00 -6.46 ± 0.04 -6.86 ± 0.05 -7.83 ± 0.06 -8.03 ± 0.04 -7.70 ± 0.05 -8.35 ± 0.30
D01 -5.29 ± 0.11 N/A -5.25 ± 0.10 N/A N/A N/A
D02 -5.89 ± 0.06 -6.48 ± 0.13 -6.32 ± 0.11 -6.65 ± 0.08 N/A N/A
D03 -5.07 ± 0.04 -5.41 ± 0.13 -5.23 ± 0.07 -5.39 ± 0.11 N/A N/A
D04 -5.09 ± 0.06 -5.46 ± 0.13 -5.25 ± 0.08 -5.51 ± 0.13 -5.22 ± 0.07 -6.12 ± 0.04
D05 -7.83 ± 0.10 -7.89 ± 0.06 -7.42 ± 0.13 -8.64 ± 0.08 -7.94 ± 0.03 -8.41 ± 0.08
D06 -7.80 ± 0.07 -7.68 ± 0.09 -7.50 ± 0.13 -8.48 ± 0.09 -7.49 ± 0.13 -7.98 ± 0.03
D07 -7.66 ± 0.08 -8.25 ± 0.09 -8.10 ± 0.05 -8.49 ± 0.10 N/A N/A
D08 -6.52 ± 0.13 -6.66 ± 0.11 -6.17 ± 0.07 -6.76 ± 0.07 -6.60 ± 0.13 -7.12 ± 0.06
D09 -6.66 ± 0.09 -7.35 ± 0.09 -7.10 ± 0.04 -7.46 ± 0.08 -6.74 ± 0.08 -7.47 ± 0.09
D10 -6.47 ± 0.12 -7.23 ± 0.09 -7.05 ± 0.04 -7.45 ± 0.09 -6.74 ± 0.08 -7.40 ± 0.09
D11 -5.77 ± 0.10 -6.17 ± 0.07 -6.27 ± 0.08 -6.45 ± 0.08 -5.66 ± 0.10 -6.42 ± 0.09
D12 -4.51 ± 0.31 -5.33 ± 0.14 -5.19 ± 0.09 -5.50 ± 0.10 -4.90 ± 0.09 -5.67 ± 0.12
D13 -4.95 ± 0.07 -5.33 ± 0.11 -5.22 ± 0.08 -5.53 ± 0.11 -5.20 ± 0.08 -5.44 ± 0.13
D14 N / AN / AN / AN / AN / AN / A
D15 -6.00 ± 0.04 -6.43 ± 0.14 -6.30 ± 0.12 -6.46 ± 0.09 -6.39 ± 0.11 -6.47 ± 0.12
D16 -6.23 ± 0.08 -6.22 ± 0.09 -6.35 ± 0.12 -6.57 ± 0.11 -6.38 ± 0.14 -6.45 ± 0.13
D17 -7.38 ± 0.14 -7.77 ± 0.09 -7.37 ± 0.11 -8.47 ± 0.13 -7.65 ± 0.10 -8.34 ± 0.11
D18 -8.50 ± 0.12 -8.45 ± 0.11 -8.31 ± 0.13 -8.29 ± 0.10 N/A N/A
D19 -8.37 ± 0.11 -8.47 ± 0.14 -8.28 ± 0.10 -8.64 ± 0.09 -8.27 ± 0.12 -8.83 ± 0.08
D20 -8.76 ± 0.10 -8.66 ± 0.13 -8.71 ± 0.11 -8.55 ± 0.09 -8.51 ± 0.14 N/A
The values are determined by cytotoxicity testing on six different cell lines. Each IC50 value represents the Effective Concentration at which 
the drug shows 50% of its efficacy on each particular cell line.Tseng et al. Molecular Cancer 2010, 9:131
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and ligands. Furthermore, suppose that probability values
μi are given as priors before any measurements are per-
formed. Suppose also the new information H in the form
of
is acquired. The preferred Pi  that codifies this new
information H and the prior is μi determined by maximiz-
ing the relative entropy given by
subject to the normalization constraint and the con-
straint in Eq. (2). The preferred posterior probability is
then given by,
where the partition function is defined in a standard
way as   and the Lagrange multiplier β
can be determined by substituting Eq. (4) back into Eq.
(2).
Information relevant to the expression level estimate
The method of ME provides a robust and universal route
for information processing with the least bias. The ME
method ensures that the ME posterior probability distri-
bution is preferred over any other probability distribu-
tions used to characterize the system of interest as long as
the information used to update from a prior is relevant to
the system. Thus, to estimate the expression levels of
tubulin isotypes in cytotoxicity assays involving the novel
colchicine derivatives, we only need to focus on deter-
mining the information that is relevant to the interactions
between tubulin isotypes and colchicine derivatives and
the relationship with the outcomes of the cytotoxicity
assays.
The interaction between tubulin isotypes and colchi-
cine derivatives (colchicine is denoted by C and its deriv-
atives are collectively denoted by C') is best described by
the binding free energy of tubulin isotypes and either C or
C'. The total binding free energy in each cell line is the
average of binding free energy of M tubulin isotypes ΔGi
with specific weighting factors Pi representing relative
expression levels of individual isotypes,
where subscript i labels the type of tubulin isotype.
Based on the ME method, 7ΔG8 if can be measured, then
the preferred weighting or the expression level can be
determined.
Although it is difficult to directly measure the binding
free energy for the entire cell line, the information regard-
ing the interaction between tubulin isotypes and colchi-
cine derivatives can still be described by the cytotoxicity
measurement of the values of log IC50. The studies of
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Table 5: Experimental tubulin isotype expression level in five cell lines
Treatment I II III IV
A549 Normal 0.264 0.268 0.462 0.006
Colchicine 0.316 0.267 0.414 0.002
D20 0.188 0.36 0.429 0.024
HeLa Normal 0.452 0.139 0.352 0.057
Colchicine 0.436 0.138 0.37 0.055
D20 0.395 0.227 0.258 0.119
MCF-7 Normal 0.112 0.596 0.291 0
Colchicine 0.168 0.499 0.333 0
D20 0.162 0.309 0.509 0.02
CEM Normal 0.279 0.16 0.56 0
Colchicine 0.852 0 0 0.148
D20 0.328 0.181 0.481 0.009
M010B Normal 0.393 0.24 0.329 0.038
Colchicine 0.446 0.19 0.259 0.106
D20 0.466 0.189 0.243 0.101Tseng et al. Molecular Cancer 2010, 9:131
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Tian and Haffner show a linear relation between cytotox-
icity-derived values of logIC50 and the binding free energy
[44],
Even though the total binding free energy can be esti-
mated from log IC50 as clearly seen from Eq. (6), we still
require the individual contribution values towards the
total binding free energy coming from tubulin isotypes
ΔGi for each of the administered colchicine derivatives.
Because of the complicated conformational changes in
the physical binding processes, calculations of the bind-
ing free energy of tubulin isotypes i and colchicine 
or colchicine derivatives   is a challenging and
demanding computational task to perform. However, we
h a v e  s u c c e e d e d  i n  t h i s  a s  h a s  b e e n  r e p o r t e d  i n  S e c . 1 .
These results will be used in the application of the ME
method as input data, along with the IC50 values obtained
from cytotoxicity measurements.
Finally, having estimated 7ΔG8 from log IC50 using ΔGi
estimates from ΔΔGbind_i, we can now re-formulate the
constraint equation that relates the cytotoxicity of colchi-
cine derivatives given by the values of log IC50 and the
binding free energy between tubulin isotypes and colchi-
cine derivatives as
where we use superscript α = C or C' to denote the cell
line exposed to colchicine or colchicine derivatives,
respectively.
ME static expression level
The ME method gives the probability distribution that is
updated from a prior μi with the information given by Eq.
(7) as
where the partition function 
and the coefficient βα is determined from Eq. (7). This will
be used as the normalized expression level of tubulin iso-
type i in the cell line exposed to colchicine derivative α.
However, because   cannot be calculated directly,
this expression level cannot be determined yet. Fortu-
nately, we can apply the ME again to resolve this issue.
Because our goal is to study the cytotoxicity of colchicine
derivatives and compare it to the case when the cells are
exposed to standard colchicine, we can utilize later stud-
ies as a prior information. Suppose the tubulin isotype
expression level when a cell line is exposed to colchicines
is given by  . We then can rewrite Eq. (8) as
where gi is a dummy variable and we set μi = 1 to indi-
cate that no other prior information is included. Further-
more, the constraint, Eq. (7) can be rewritten as
Therefore, the binding free energy involving a tubulin
isotype and colchicine can be estimated from
 through Eqs. (9) and (10). Next, since
, the binding free energy
involving a tubulin isotype and colchicine derivatives is
.
Therefore, we can determine the expression level of tubu-
lin isotype i in cell lines exposed to colcichine-based
derivatives by
where we consider the normalized expression level
 as the prior μi. Furthermore, the practically of Eq.
(11) requires an initial guess of βC' in order to solve Eq.
(7). In our studies, in order to generate a statistically rele-
va n t  da t a  s e t,  w e  wi l l  r e pea t  t h e  s a m e  ca l cu la t i o n  o n e
hundred times with various initial guesses for βC' gener-
ated by random selection. Both the mean value βC' and its
standard deviation will be used in our calculations.
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Results and Discussion
Validation and the effects of different prior information
To validate the proposed approach, we consider the cell
lines used except M006X and one colchicine derivative
D20 as the benchmark because of the sufficient experi-
mental expression data for these five cell lines exposed to
D20 (see Table 5). We also investigate the effects of differ-
ent prior information required in the proposed approach.
Because the tubulin isotypes αβIIa and αβIIb are struc-
turally indistinguishable in some experiments, as are the
isotypes αβIVa and αβIVb, we average relative binding
energy of isotypes αβIIa and αβIIb and isotypes αβIVa
and  αβIVb as isotypes αβII and αβIV, respectively, to
account for this property.
Results for no experimental expression data available
Suppose there is not enough experimental expression of
tubulin isotypes in cell lines exposed to colchicine, the
optimal choice then is to assume that the five tubulin iso-
types are equally expressed in cell lines based on Ber-
noulli's principle of insufficient reason [45]. Therefore,
we propose to set a uniform prior,  , where M
denotes the total number of tubulin isotypes in the pro-
posed approach. We can then estimate the expression
level of tubulin isotypes in five cell lines with D20 present
from Eqs. (9), (10) and (11). Figure 4 shows the ME
results and compares them to the experimental measure-
ment values denoted by histogram. The open squares are
calculated using the mean relative binding free energy
and will be taken to represent the mean ME expression
level of tubulin isotypes. The dark and light gray bars are
obtained using mean plus and minus standard deviation
(SD) of relative binding free energy, respectively, and they
will be noted as mean ± SD ME expression level.
The ME predictions based on mean relative binding
fr ee  ene r gy va lu es  a nd m ean pl us  and m in us  sta nda r d
deviations all give roughly the same trends for all five cell
lines. However, this only agrees with the experimental
observations for the cell line A549, MCF-7 and CEM. We
believe that the reason for this finding is that the expres-
sion levels of tubulin isotypes in cell lines exposed to
colchicine except A549, MCF-7 and CEM are dramati-
cally different from the uniform prior, which was taken to
represent uniform expression levels for all tubulin iso-
types. For the case of no prior information including in
the calculation, these results are simply resulted from that
D20 and isotype αβIII has the largest relative binding free
energy.
Results for the case with limited experimental expression data 
available
Whenever the expression data for tubulin isotypes in cell
lines exposed to colchicine is available, we considered the
normalized expression level as the prior  . Therefore,
having obtained the expression data measured in five cell
lines exposed to D20, the ME calculations are shown in
figure 5 with the same definitions of symbols as those in
figure 4. This figure shows several key features emerging
from ME calculations. First, in A549 and MCF-7, the fig-
ure shows the experimental observations are almost dis-
tributed within the mean ± SD ME expression levels
again. Second, for HeLa and M006B, the mean-SD ME
expression levels are almost coincide with the experimen-
tal observations.
I t  s h o u l d  be  e m p h as iz ed  t h a t  t h e  c h o i c e  o f  a  " g ood "
prior and accurate binding free energy estimates are cru-
cial. As shown in both cases, when the prior takes into
account the experimental expression data and appropri-
ate relative binding free energy, the proposed approach is
likely to give correct tubulin expression levels. However,
one should not dismiss the use of the uniform prior. One
can expect the ME calculation with the uniform prior to
predict the expression levels similar to experimental
observations when the variations of actual expression lev-
els for tubulin isotypes in cell lines exposed to colchicine
are not dramatically differed from the uniform distribu-
tion. Cell line A549 and MCF-7 are excellent examples of
this type of outcome.
Next, we will utilize the prior assigned from experi-
mental data to further investigate two questions, namely:
"What are the expression levels of tubulin isotypes in cell
lines exposed to various colchicine derivatives?" and
"What are the predicted tubulin isotype expression levels
when the similar isotype pairs: αβIIa and αβIIb, and
αβIVa and αβIVb are distinguishable in cell lines with the
presence of different derivatives?"
ME expression levels of tubulin isotypes when cell lines are 
exposed to all derivatives
Case 1
Tubulin isotype αβIIa and αβIIb as well as αβIVa and
αβIVb are considered to be structurally indistinguishable
Tubulin isotype αβIII is a primary target of colchicine 
derivatives D01, D02, D03, D04, D05, D06, D18 and D20
All six cell lines are studied given the tubulin isotypes
expression levels in each cell line exposed to colchicines
as a prior. When the ME predicted expression level for a
given colchicine derivative cannot be determined, zero
PM i
eC =1/
Pi
eCTseng et al. Molecular Cancer 2010, 9:131
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expression levels are assigned. One can attribute it to the
fact that relative binding free energy given such a deriva-
tive is ill defined. There is no solution for Eq. (7). The
results of our analysis are plotted in figure 6.
We further summarize and illustrate the tubulin isotype
distribution with the highest expression levels in cell lines
exposed to the twenty colchicine derivatives in figure 7 to
investigate the effects of the colchicine derivatives on the
expression levels of tubulin. Note that the colchicine
derivatives are plotted in the order of potency from weak
at bottom toward strong at top based on the correspond-
ing IC50  values. The remaining labels show the same
order of tubulin isotype expression. The figure shows sev-
eral important features. First, tubulin isotype αβIII is
likely to show the highest expression level for the cell line
A549, Hela, M010B and M006X exposed to the colchi-
cine derivatives D03, D04, D05, and D20. For MCF-7, it
has the highest expression level for the colchicine deriva-
tives D03, D04, and D06. Second, for colchicine deriva-
tives D09 and D13, Figure 7 shows that isotype αβI has
the highest expression level in all cell lines except MCF-7
and CEM. Furthermore, it also has the highest level for
cell line CEM with three out of five derivatives. Third, for
cell line MCF-7, it is either isotype αβII or αβIII that has
the highest expression level. Finally, the frequency score
of the isotypes with the highest expression level is 13, 7,
26, 5, 35 and 28 for the tubulin isotypes αβI, αβII, αβIII,
αβIV, labelled "U" and "0", respectively. Isotype αβIII is
ranked first and is followed by αβI and αβII over all.
Fourth, Figure 5 shows no obvious correlation between
the potency of derivatives and the isotypes with the high-
est expression level, particularly, αβIII, the potency is
Figure 4 The ME expression levels with the consideration of a uniform prior The ME expression levels of four tubulin isotypes in five cell lines 
exposed to D20 with the consideration of a uniform prior. The hollow square denotes the ME expression level calculated based on mean relative bind-
ing free energy ΔΔGbind_i. The black and gray bar are the ME expression level calculated based on mean ΔΔGbind_i ± its standard deviation (SD). The 
histogram with sparse oblique strips denotes experimental expression level data.Tseng et al. Molecular Cancer 2010, 9:131
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unlikely a factor to influence the binding affinity. Finally,
this suggests that tubulin isotypes αβIII followed by αβI
and αβII are the first three primary targets of colchicine
derivatives in all cell lines except CEM giving us impor-
tant insights for future optimization of drug design based
on colchicine derivatives.
Case 2
Only tubulin isotype αβIVa and αβIVb are structurally
distinguishable
Both isotype αβIVa and IVb have relatively low expression 
levels
Next, we study the application of ME method to the case
when tubulin isotype αβIVa and αβIVb are structurally
distinguishable in cell lines. Because experimental mea-
surements on expression levels are only available for the
isotype αβIV, we simply assign both αβIVa and IVb with
the same prior, which is half of the normalized expression
level of isotype αβIV for the calculations. Furthermore,
we only take A549 cell line as an example for our investi-
gations (see figure 8). In general, the difference between
isotype αβIVa and αβIVb does not influence the trend of
expression levels for the case when tubulin isotypes
αβIVa and αβIVb are indistinguishable. There is only one
case using D09 that shows results opposite to the one
from figure 6. We therefore concluded that there is no
solution for this particular case.
In addition, there is no major difference between both
isotypes with both having relatively low expression levels
for cell line A549 exposed to all colchicine derivatives, yet
for derivative D11, the isotype αβIVb has a higher expres-
sion level than tubulin αβIVa.
Figure 5 The ME expression levels with the consideration of prior estimated from colchicine data. ME expression levels of four tubulin isotypes 
in five cell lines exposed to D20 with the consideration of prior estimated from experimental data for colchicine. The hollow square denotes the ME 
expression level calculated based on mean relative binding free energy ΔΔGbind_i. The black and gray bar are the ME expression level calculated based 
on mean ΔΔGbind_i ± its standard deviation (SD). The histogram with sparse oblique strips denotes experimental expression level data.Tseng et al. Molecular Cancer 2010, 9:131
http://www.molecular-cancer.com/content/9/1/131
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Case 3
All tubulin isotypes are structurally distinguishable
Tubulin isotype αβIII is the primary target for twelve out of 
twenty colchicine derivatives
We then investigated the effects when all tubulin isotypes
are structurally distinguishable in the cell line A549. In
general, when we take the differences between tubulin
isotypes αβIIa and αβIIb in addition to αβIVa and αβIVb
into account, the ME calculation shows that the scorefor
the tubulin isotype αβIII when it has the highest expres-
sion level in the cell line A549 is increased from 8 to 13
(see figure 9). This observation suggested that tubulin
isotype αβIII is a primary target for twelve out of twenty
derivatives.
Figure 6 The ME expression levels with the consideration of prior estimated from colchicine data. The ME expression levels of four tubulin iso-
types in six cell lines exposed to twenty colchicine derivatives. Color labels the cell lines. Note that D14 is removed since there is no sufficient data for 
the calculations.Tseng et al. Molecular Cancer 2010, 9:131
http://www.molecular-cancer.com/content/9/1/131
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The expression level of tubulin isotype αβIIa and αβIIb 
shows two trends
For D01, 11, 13 and 15, the ME calculation shows that
tubulin isotype αβIIa has a higher expression level than
αβIIb. However, when A549 is exposed to D05, D08, D16,
D17 and D20, the calculation shows the opposite trend
that isotype αβIIb is expressed over αβIIa. For the rest of
derivatives D03, 04, 06, D18, both roughly have the same
expression level.
We have applied the maximum entropy approach to
predict the tubulin isotype expression levels to study
cytotoxic effects due to the binding of tubulin isotypes in
several human cancer cell lines subjected to a panel of
colchicine derivatives. Experimental assays leading to this
report and performed by us include cytotoxicity on can-
cer cell lines for each of the 20 drug molecules from the
same family of colchicine compounds. The tubulin iso-
type expression level measurements were performed
under three conditions in the cell lines, which received no
treatment (normal), were exposed to colchicine and were
exposed to the compound D20. The maximum entropy
method is used in conjunction with binding energy calcu-
lations for the colchicine derivatives, as they were found
to interact specifically with tubulin isotypes. We found
that depending on the use of assumptions regarding the
priors in the method applied to the probability distribu-
tion functions, various outcomes may be obtained. How-
ever, in the presence of experimentally available
information, a much more consistent picture emerges.
Most importantly, in almost all cases studied we have
identified the tubulin isotype αβIII as the first most
important molecular target for the action of the colchi-
cine derivatives that inhibit the polymerization of MTs.
We have also found the isotypes αβI and αβII as second-
ary targets but their significance is substantially dimin-
ished due to the widespread expression throughout the
human body, especially true for αβI, in contrast to αβIII
which is limited to a few specific tissues and cancer cells.
Conclusions
We have demonstrated the applicability of the maximum
entropy approach in predicting cytotoxic effects based on
limited information such as the relative binding energy
values for the cytotoxic agents used. Namely, given the
relative binding free energy of tubulin isotype and colchi-
cine derivatives, the proposed approach predicts the
tubulin isotype expression levels in various cell lines
exposed to colchicine derivatives. Our studies also pro-
vide a better defined molecular target for the action of
these anti-mitotic drugs, namely, tubulin isotype αβIII,
Figure 7 Plot of colchicine derivatives vs. cell lines. The distribution of tubulin isotypes with the highest expression levels in six cell lines, where 
they are exposed to 20 colchicine derivatives. The color map level 1 to 5 indicates the types of tubulin isotypes. Label "U" denotes that there are mul-
tiple isotypes that have the same highest expression level. Label "0" denotes no ME prediction can be made. All the colchicine derivatives are sorted 
in the order of potency (logIC50 value).Tseng et al. Molecular Cancer 2010, 9:131
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for optimized chemotherapy drug design compared to
earlier efforts in this area. By narrowing down the focus
of tubulin targets to this isotype, most dramatically regu-
lated by cancer cells when exposed to the colchicine
derivatives, both the efficacy and specificity of treatment
will hopefully be improved.
Unfortunately, the currently used chemotherapy drugs
do not particularly target αβIII tubulin isotype, hence the
Figure 8 The ME expression levels in A549 with Tubulin isotypes IVa and IVb are distinguishable. The ME predictions for the expression levels 
of the five tubulin isotypes in the cell line A549 exposed to twenty colchicine derivatives. Tubulin isotypes IVa and IVb are assumed to be distinguish-
able. Note that N/A indicates no solution can be found.Tseng et al. Molecular Cancer 2010, 9:131
http://www.molecular-cancer.com/content/9/1/131
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Figure 9 The ME expression levels in A549 with all Tubulin isotypes are distinguishable. The ME expression levels of five tubulin isotypes in cell 
line A549 exposed to twenty colchicine derivatives. All Tubulin isotype are considered to be distinguishable. Note that N/A indicates no solution can 
be found.
best compounds revealed in this study may offer a poten-
tial improvement in clinical outcomes. An interesting
question to ask is why the currently used compounds
show good efficacies without specifically targeting tubu-
lin isotype αβIII. The probable reason why taxanes and
vinblastine are successful is that they preferentially inter-
act with the αβII isotype [3,46] which is widespread in
cancers [47], but has a somewhat limited distribution inTseng et al. Molecular Cancer 2010, 9:131
http://www.molecular-cancer.com/content/9/1/131
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normal cells, being found largely in nerves and at low lev-
els elsewhere [19,48]. Not surprisingly, these drugs cause
neurotoxicity [49-51]. In contrast, the parent compound
colchicine prefers to bind to αβIV, an isotype widespread
in normal tissues that is not common in cancers [7].
Hence, prolonged chemotherapy with colchicines would
not be useful due to severe side effects such as kidney and
liver toxicity.
The αβIII isotype of tubulin singled out in the present
paper is an almost perfect target for breast cancer chemo-
therapy because a) it is found in many tumors, especially
those that are metastatic and aggressive, including breast
tumors [21,52-55]; and b) its normal distribution is even
more limited than that of αβII, occurring largely in the
brain and the testes [19]. αβIII accounts for only 25% of
brain αβ-tubulin while αβII constitutes 58% [56] suggest-
ing a reduced neurotoxicity [57]. Furthermore, while αβII
is found in both neurons and glial cells, αβIII occurs only
in neurons [48].
Other researchers have already realized that αβIII
would be an excellent target for anti-tumor drugs [58]
and have attempted to use rational drug design to create a
αβIII-specific drug. The seco-taxoid, IDN 5390 [25,59]
was explicitly designed to bind to the taxane binding site
on  αβIII. This drug is very effective against paclitaxel-
resistant cell lines over-expressing αβIII. The epothilone
derivative ixabepilone which is very effective against
human cancer cell lines and xenograft models that over-
express  αβIII and under-express αβII, is now recom-
mended for use with metastatic taxane-resistant or tax-
ane-untreated breast cancers [60,61]. However, despite
being apparently very promising, these new drugs may
have some serious limitations. First, it has now been
shown experimentally in vitro that either ixabepilone or
IDN 5390 binds well to αβIII and poorly to other isotypes.
The in vivo data indeed indicate that these compounds
target αβIII [59,60] but do not rule out their strong bind-
ing to other isotypes. Second, the observation that
ixabepilone has the same toxicity profile as paclitaxel,
including neuropathy [61,62], and the fact that IDN 5390
is recommended to be used in conjunction with taxanes
[25] indicates that the neurotoxicity issue is still not
resolved. Third, it may be that the fundamental problem
with the process that led to the design of these drugs is
that no effort was made to figure out the actual physio-
logical function of their intended target: the αβIII iso-
type---nor of the targets to be avoided, such as the αβI or
αβII isotypes.
On the other hand, our novel colchicine derivatives
bind at a different site on tubulin than do either IDN 5390
or ixabepilone. Thus, we are exploring a new area here.
There is no reason to expect these derivatives to have the
same toxicity and side effects as does colchicine, the par-
ent compound. Since its toxicity arises from the fact that
standard colchicine has a very high affinity for the wide-
spread αβIV isotype, while it binds very poorly to αβIII.
These novel compounds were designed to bind well to
αβIII and hence should not cause the same type of toxic-
ity as does colchicines.
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